Chronic Myeloid Leukemia
Author and Disclosure Information [Show]

Kathryn E. Beckerman, MD, PhD
Clinical Fellow, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

Michael R. Savona, MD
Associate Professor, Division of Hematology/Oncology, Vanderbilt- Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

Question 1 of 5

A 65-year-old man presents to his primary care physician for a regularly scheduled check-up. Routine blood work demonstrates a white blood cell (WBC) count of 34,000/µL. He is referred to hematology for follow-up regarding his complete blood count (CBC), which is concerning for chronic myeloid leukemia (CML). He is found to have t(9;22) on FISH (fluorescence in situ hybridization) and, following a discussion between the patient and physician, he is started on imatinib 400 mg daily. During the first month, the patient tolerates this therapy well and has no cytopenias or abnormalities on liver function testing.

After the first month, how should this patient be monitored on therapy?

Bone marrow biopsy and karyotype every 6 months

CBC and bone marrow biopsy every 3 months

CBC every month with bone marrow biopsy every 3 months

Quantitative polymerase chain reaction (PCR) every 3 months and consideration of bone marrow biopsy at 1 year

Hospital Physician: Hematology/Oncology. 2015 July;11(4)

This quiz is not accredited for CME.

More from Board Review Questions: Hematology/Oncology


Autoimmune Hemolytic Anemia
Gastrointestinal Stromal Tumors
Testicular Cancer
Management of Advanced Melanoma
Castration-Resistant Prostate Cancer
Transfusion Reactions (part 2)
Transfusion Reactions (part 1)
Plasma Cell Disorders (part 3)
Plasma Cell Disorders (part 2)
Chronic Myeloid Leukemia
Aplastic Anemia
Small Cell Lung Cancer
Management of Metastatic Gastric Cancer
Transfusion Medicine
Management of Colorectal Cancer in Older Adults
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease
Acute Myeloid Leukemia
HER2-Positive Breast Cancer
Aggressive B-Cell Non-Hodgkin Lymphoma
Pancreatic Adenocarcinoma: Advanced Unresectable and Metastatic Disease
Von Willebrand Disease: Assessment and Diagnostic Testing
Von Willebrand Disease: Clinical Management
Pancreatic Adenocarcinoma: Neoadjuvant and Adjuvant Treatment
Late Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Polycythemia Vera and Essential Thrombocythemia: Current Management
Treatment of Biliary Tract Cancers
Early Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Hairy Cell Leukemia
Genomic Testing in Women with Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Immune Thrombocytopenia
Cancer-Related Fatigue
Disseminated Intravascular Coagulation
Advanced Stage and Relapsed/Refractory Hodgkin Lymphoma
Adjuvant Chemotherapy for Colon Cancer
Molecular Markers and Targeted Therapies in the Management of Non-Small Cell Lung Cancer
Metastatic Cutaneous Melanoma: Targeted Therapy and Immunotherapy
Thrombosis in Pregnancy
Locally Advanced Pancreatic Cancer
Early-Stage Hodgkin Lymphoma
Neoadjuvant and Adjuvant Therapy for Gastric Cancer
Hemophilia A and B
Mantle Cell Lymphoma
Soft Tissue Sarcoma
Sickle Cell Disease
Renal Cell Carcinoma
Management of Locally Advanced Rectal Adenocarcinoma
Adjuvant Systemic Therapy for Early-Stage Breast Cancer
Plasma Cell Disorders
Myelodysplastic Syndromes
Acute and Chronic Graft-versus-Host Disease